Bioregenx (BRGX) Common Equity (2021 - 2026)

Bioregenx's Common Equity history runs 6 years deep, the most recent figure standing at -$4.5 million for Q1 2026.

• On a quarterly basis, Common Equity fell 27.38% year-over-year to -$4.5 million in Q1 2026; TTM through Mar 2026 was -$4.5 million, a 27.38% decrease from a year earlier, with the FY2025 full-year figure at -$4.5 million, down 34.27% from the prior year.
• Common Equity was little changed at -$4.5 million in Q1 2026 per BRGX's latest filing, from -$4.5 million in the prior quarter.
• Across five years, Common Equity topped out at $15.1 million in Q1 2024 and bottomed at -$4.5 million in Q4 2025.
• The 5-year median for Common Equity is -$2.5 million (2022), against an average of $391273.8.
• Across the five-year window, Common Equity tumbled 2901.09% in 2022 and surged 724.59% in 2024, its largest moves.
• Year by year, Common Equity stood at -$2.5 million in 2022, then increased by 18.06% to -$2.1 million in 2023, then sank by 63.14% to -$3.4 million in 2024, then sank by 34.27% to -$4.5 million in 2025, then rose by 0.09% to -$4.5 million in 2026.
• Per Business Quant, the three latest BRGX Common Equity figures stand at -$4.5 million (Q1 2026), -$4.5 million (Q4 2025), and -$3.6 million (Q3 2025).